Literature DB >> 22806098

Natural and long-lasting cellular immune responses against influenza in the M2e-immune host.

M Schotsaert1, T Ysenbaert, K Neyt, L I Ibañez, P Bogaert, B Schepens, B N Lambrecht, W Fiers, X Saelens.   

Abstract

Influenza is a global health concern. Licensed influenza vaccines induce strain-specific virus-neutralizing antibodies but hamper the induction of possibly cross-protective T-cell responses upon subsequent infection.(1) In this study, we compared protection induced by a vaccine based on the conserved extracellular domain of matrix 2 protein (M2e) with that of a conventional whole inactivated virus (WIV) vaccine using single as well as consecutive homo- and heterosubtypic challenges. Both vaccines protected against a primary homologous (with respect to hemagglutinin and neuraminidase in WIV) challenge. Functional T-cell responses were induced after primary challenge of M2e-immune mice but were absent in WIV-vaccinated mice. M2e-immune mice displayed limited inducible bronchus-associated lymphoid tissue, which was absent in WIV-immune animals. Importantly, M2e- but not WIV-immune mice were protected from a primary as well as a secondary, severe heterosubtypic challenge, including challenge with pandemic H1N1 2009 virus. Our findings advocate the use of infection-permissive influenza vaccines, such as those based on M2e, in immunologically naive individuals. The combined immune response induced by M2e-vaccine and by clinically controlled influenza virus replication results in strong and broad protection against pandemic influenza. We conclude that the challenge of the M2e-immune host induces strong and broadly reactive immunity against influenza virus infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22806098     DOI: 10.1038/mi.2012.69

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  24 in total

1.  Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant.

Authors:  Jan Tavernier; Sarah Gerlo; Bram Van Den Eeckhout; Lien Van Hoecke; Elianne Burg; Sandra Van Lint; Frank Peelman; Niko Kley; Gilles Uzé; Xavier Saelens
Journal:  NPJ Vaccines       Date:  2020-07-23       Impact factor: 7.344

2.  M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.

Authors:  D G Eliasson; A Omokanye; K Schön; U A Wenzel; V Bernasconi; M Bemark; A Kolpe; K El Bakkouri; T Ysenbaert; L Deng; W Fiers; X Saelens; N Lycke
Journal:  Mucosal Immunol       Date:  2017-03-01       Impact factor: 7.313

3.  Functional Comparison of Mx1 from Two Different Mouse Species Reveals the Involvement of Loop L4 in the Antiviral Activity against Influenza A Viruses.

Authors:  Judith Verhelst; Jan Spitaels; Cindy Nürnberger; Dorien De Vlieger; Tine Ysenbaert; Peter Staeheli; Walter Fiers; Xavier Saelens
Journal:  J Virol       Date:  2015-08-19       Impact factor: 5.103

4.  Akt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro.

Authors:  Oxana V Denisova; Sandra Söderholm; Salla Virtanen; Carina Von Schantz; Dmitrii Bychkov; Elena Vashchinkina; Jens Desloovere; Janne Tynell; Niina Ikonen; Linda L Theisen; Tuula A Nyman; Sampsa Matikainen; Olli Kallioniemi; Ilkka Julkunen; Claude P Muller; Xavier Saelens; Vladislav V Verkhusha; Denis E Kainov
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

5.  Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice.

Authors:  Lei Deng; Timothy Z Chang; Ye Wang; Song Li; Shelly Wang; Shingo Matsuyama; Guoying Yu; Richard W Compans; Jian-Dong Li; Mark R Prausnitz; Julie A Champion; Bao-Zhong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-31       Impact factor: 11.205

6.  Safe Recombinant Outer Membrane Vesicles that Display M2e Elicit Heterologous Influenza Protection.

Authors:  Hannah C Watkins; C Garrett Rappazzo; Jaclyn S Higgins; Xiangjie Sun; Nicole Brock; Annie Chau; Aditya Misra; Joseph P B Cannizzo; Michael R King; Taronna R Maines; Cynthia A Leifer; Gary R Whittaker; Matthew P DeLisa; David Putnam
Journal:  Mol Ther       Date:  2017-02-16       Impact factor: 11.454

7.  A Novel Vaccination Strategy Mediating the Induction of Lung-Resident Memory CD8 T Cells Confers Heterosubtypic Immunity against Future Pandemic Influenza Virus.

Authors:  Yu-Na Lee; Young-Tae Lee; Min-Chul Kim; Andrew T Gewirtz; Sang-Moo Kang
Journal:  J Immunol       Date:  2016-02-10       Impact factor: 5.422

8.  Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge.

Authors:  Francisco Miguel Cardoso; Lorena Itatí Ibañez; Silvie Van den Hoecke; Sarah De Baets; Anouk Smet; Kenny Roose; Bert Schepens; Francis J Descamps; Walter Fiers; Serge Muyldermans; Ann Depicker; Xavier Saelens
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

9.  Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice.

Authors:  Sarah De Baets; Bert Schepens; Koen Sedeyn; Michael Schotsaert; Kenny Roose; Pieter Bogaert; Walter Fiers; Xavier Saelens
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

10.  Tetramerizing tGCN4 domain facilitates production of Influenza A H1N1 M2e higher order soluble oligomers that show enhanced immunogenicity in vivo.

Authors:  Sweety Samal; Tripti Shrivastava; Praveen Sonkusre; Zaigham Abbas Rizvi; Rajesh Kumar; Shubbir Ahmed; Preeti Vishwakarma; Naveen Yadav; Manish Bansal; Kanchana Chauhan; Sebanta Pokhrel; Supratik Das; Padmakar Tambare; Amit Awasthi
Journal:  J Biol Chem       Date:  2020-08-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.